Assay identified 98% of relapses and 100% of cutaneous melanoma-related deaths in stage IB/IIA patients Patients with stage IB/IIA melanoma identified as high-risk had a relapse rate comparable
Jonathan Yang, MD, PhD, joined New York City-based NYU Langone Health s Perlmutter Cancer Center as director of clinical research at its Brain and Spine Tumor C
Michelle Krogsgaard, PhD, discusses the identification and potentially utility of phosphorylated neoantigen targets for anticancer vaccine development.